Ambrx Biopharma Inc. AMAM NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score

28/100

0/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Ambrx Biopharma Inc. (AMAM) generated $-18.88M in operating cash flow for quarter ending 2023-09-30. After capital expenditures of $298K, free cash flow was $-19.18M.

Free cash flow margin was -36179.2% of revenue. Cash conversion ratio was 0.82x, suggesting some earnings are non-cash.

Criteria supported by this page:

HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
MOAT (58/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
INCOME (10/100) — Cash conversion ratio was 0.82x suggests some earnings are non-cash items

Overall SharesGrow Score: 28/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

28/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

✗

FUTURE

20/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

HEALTH

67/100

Debt-to-Equity & liquidity

Proven by this page

MOAT

58/100

Proven by this page

✗

GROWTH

15/100

→ Income

✗

INCOME

10/100

→ Income

Ambrx Biopharma Inc. Cash Flow History

Metric	TTM	Q3 FY2023	Q2 FY2023	Q1 FY2023	Q4 FY2022
Operating Cash Flow	$-57.7M	$-18.88M	$-13.15M	$-12.97M	$-12.7M
Capital Expenditure	$-1.13M	$-298K	$-783K	$0.00	$-47K
Free Cash Flow	$-58.83M	$-19.18M	$-13.93M	$-12.97M	$-12.75M